by Scott Larrivee | Jun 19, 2025 | News
Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
by Scott Larrivee | May 16, 2025 | Podcast
In this episode, Milton Lönnroth, Co-Founder and CEO, shares how Atley Solutions is changing the game for astatine-211, a promising isotope in cancer therapy. Atley supports radiopharmaceutical companies and researchers by enabling the scalable production and labeling...
by Scott Larrivee | Jan 16, 2025 | News
Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply VALENCIA, Calif. and GOTHENBURG, Sweden – Jan. 16, 2025 – Nusano, a...
by Scott Larrivee | Oct 17, 2024 | News
Image above: Starget Pharma, stargetpharma.com VALENCIA, Calif. and TEL AVIV, Israel – Oct. 17, 2024 – Nusano, a physics company transforming the production of radioisotopes, and Starget Pharma, a clinical-stage biotechnology company developing precision peptide...
by Scott Larrivee | Jul 10, 2024 | News
VALENCIA, Calif. and BOCA RATON, Fla. – July 10, 2024 – Nusano Inc. (Nusano), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. (PharmaLogic), a leading radiopharmaceutical contract development and manufacturing...
